FDA approves pembrolizumab/lenvatinib for advanced endometrial cancer


  • Deepa Koli
  • Oncology drug update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The FDA has granted accelerated approval to pembrolizumab+lenvatinib for the treatment of patients with advanced endometrial cancer who have disease progression after prior systemic therapy. 
  • The indication applies to patients who are not candidates for surgery or radiation and have disease that is not microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR).
  • Recommended dose: 20 mg oral lenvatinib once daily with pembrolizumab 200 mg every 3 weeks.

Why this matters

  • Review decisions were simultaneous in the United States, Australia, and Canada under Project Orbis.
  • The Real-Time Oncology Review (RTOR) pilot program allowed FDA data review before application submission. 

Key points

  • Approval was based on the single-group, open-label KEYNOTE-146 study of 108 patients with metastatic endometrial carcinoma who progressed after ≥1 prior systemic therapy.
  • 94 patients did not have MSI-H or dMMR tumors:
    • Objective response rate was 38.3% (complete responses, 10.6% and partial responses, 27.7%).
    • Median duration of response was not reached; 69% of responders had response durations ≥6 months.
  • Tumor MSI status was determined using a polymerase chain reaction test and MMR status, using an immunohistochemistry test.
  • The most common adverse reactions (≥20%) were fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting.

Prescribing Information

Pembrolizumab

Lenvatinib